Curtis Hecht is Chief Business Officer of Tallac Therapeutics. He brings 25 years of broad pharmaceutical experience including business development, strategic planning and commercialization. Previously, as CBO of Calithera Biosciences, he led the Business Development and Product Strategy Group and was responsible for closing a number of licensing and clinical collaboration agreements, built the portfolio management and lifecycle functions and led commercial planning. Prior to Calithera, Mr. Hecht was Vice President of Business Development for inVentiv Heath, was as a Partner of the consulting firm, DNA Ink and spent 9 years at Roche/ Genentech in commercialization and business development roles where he was involved in a number of transactions, including the $47 billion acquisition of Genentech. Mr. Hecht has a B.S. in Chemistry from California State University, Sacramento, and an MBA from Carnegie Mellon University.